1912422-56-0
1912422-56-0 structure
- Name: NFATc1-IN-1
- Chemical Name: NFATc1-IN-1
- CAS Number: 1912422-56-0
- Molecular Formula: C13H8F2INO2
- Molecular Weight: 375.11
- Catalog: Research Areas Others
- Create Date: 2022-09-30 00:03:47
- Modify Date: 2026-08-23 23:28:16
-
NFATc1-IN-1 (compound A04) is a potent inhibitor of RANKL-induced osteoclast formation, with an IC50 of 1.57 μM. NFATc1-IN-1 shows anti-osteoclastogenic effects through reducing the RANKL-induced nuclear translocation of NFATc1. NFATc1-IN-1 can be used for osteoclastic diseases research[1].
| Name | NFATc1-IN-1 |
|---|
| Description | NFATc1-IN-1 (compound A04) is a potent inhibitor of RANKL-induced osteoclast formation, with an IC50 of 1.57 μM. NFATc1-IN-1 shows anti-osteoclastogenic effects through reducing the RANKL-induced nuclear translocation of NFATc1. NFATc1-IN-1 can be used for osteoclastic diseases research[1]. |
|---|---|
| Related Catalog | |
| In Vitro | NFATc1-IN-1 (compound A04) (0-2.5 μM, 4 days) exhibits potent inhibitory activities on osteoclast formation and function, which eventually translates into decreased bone resorption[1]. NFATc1-IN-1 (1.5-2.5 μM, 24 h) blocks NFATc1 nuclear translocation and decreases the level of NFATc1[1]. Cell Viability Assay[1] Cell Line: Osteoclast precursor RAW 264.7 cells Concentration: 0, 0.5, 1.0, 1.5, 2.0 and 2.5 μM Incubation Time: 4 days Result: Markedly reduced the number and size of red TRAP-positive multinucleated osteoclasts at concentrations of 1.5, 2.0, and 2.5 μM. Significantly inhibited formation of osteoclasts in a dose-dependent manner (at 1.5, 2.0 and 2.5 μM), while showing no cytotoxic effects towards osteoclast precursor cells at concentrations of as high as 2.5 μM. Immunofluorescence[1] Cell Line: RAW264.7 cells Concentration: 1.5 or 2.5 μM Incubation Time: 24 h Result: Blocked NFATc1 nuclear translocation and decreased the level of NFATc1. |
| References |
| Molecular Formula | C13H8F2INO2 |
|---|---|
| Molecular Weight | 375.11 |